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ABSTRACT 
 
We aimed to determine the efficacy of the 10-valent pneumococcal-Haemophilus influenzae protein D 
conjugate vaccine (PHiD-CV) in children aged 18-months to <18-years with recurrent protracted 
bacterial bronchitis (rPBB), chronic suppurative lung disease (CSLD) or bronchiectasis. In a multi-
centre, double-blind randomised controlled trial, children received two doses, 2-months apart of the 
10vPHiD-CV or quadrivalent meningococcal-ACYW135 conjugate vaccine. Active surveillance for 
acute exacerbations, respiratory symptoms and antibiotic use was undertaken through to 12-months 
after the second vaccine dose (clinical cohort only). Serum, saliva and nasopharyngeal swabs were 
collected to measure immunological and microbiological effects (immunology cohort). Between 
December 2012 and August 2015, 62 children were enrolled onto the clinical protocol (1 excluded 
from clinical analyses due to unblinding), while 74 contributed to the immunology cohort (overall 
mean age=6.8-years (standard deviation=3.7), 42 (56.8%) male). The absolute risk difference 
comparing the 10vPHiD-CV group (n=31 children) to the MenACYW135 group (n=30 children) for 
acute exacerbations was -0.5 exacerbations/100-weeks at risk (95% confidence interval (CI)  
-2.0, 0.9). Compared to the MenACYW135 group, children who received the 10vPHiD-CV were less 
likely to have respiratory symptoms in each fortnight of surveillance (incidence density ratio (IDR) 
0.82, 95%CI 0.61, 1.10) and required fewer short-course (<14-days duration) antibiotics (IDR 0.81, 
95%CI 0.61, 1.09). The vaccine was immunogenic and no serious adverse events related to the 
vaccine were reported. In conclusion, 10vPHiD-CV might have a future role in managing children 
with rPBB, CSLD and bronchiectasis, but larger multicentre trials are needed to confirm or refute 
findings from this preliminary study.  
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ABBREVIATIONS IN TEXT 
 
CI   confidence interval 
CSLD   chronic suppurative lung disease 
DSMC   Data Safety Monitoring Committee 
GMT   geometric mean titre 
Hi   Haemophilus influenzae 
IDR   incidence density ratio 
MenACYW135  quadrivalent meningococcal conjugate ACYW135 vaccine 
NPS   nasopharyngeal swab 
NTHi   non-typeable Haemophilus influenzae 
PBB   protracted bacterial bronchitis 
PCV   pneumococcal conjugate vaccine 
PD   protein D 
PHiD-CV  10-valent pneumococcal-Haemophilus influenzae protein D conjugate  
   vaccine  
PPV23   23-valent pneumococcal polysaccharide vaccine 
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PV   pneumococcal vaccines 
RCT   randomised controlled trial 
rPBB   recurrent protracted bacterial bronchitis 
SAE   serious adverse event 
BACKGROUND 
 
Persistent wet cough, a key feature in a group of paediatric chronic pulmonary disorders, is 
increasingly appreciated because of the burden it causes to the child, family and healthcare sector.
1,2
 
These disorders, dominated by protracted bacterial bronchitis (PBB), chronic suppurative lung disease 
(CSLD) and bronchiectasis (Box 1), have in common impaired mucociliary clearance and lower 
airway bacterial infection and inflammation.
3,4
  
 
Haemophilus influenzae (Hi) (usually unencapsulated or non-typeable (NTHi) strains) is consistently 
the most common bacterial pathogen isolated from the lower airways of children with PBB, CSLD or 
bronchiectasis, followed less often by Streptococcus pneumoniae (pneumococcus) and Moraxella 
catarrhalis.
5,6
 Despite childhood immunisation with pneumococcal and encapsulated Hi type b 
conjugate vaccines, these chronic disorders are commonly seen in paediatric respiratory practice.
5
 
Acute exacerbations are especially important as not only are they are associated with lower quality of 
life scores,
1
 but the frequency of severe episodes leading to hospitalisation predicts pulmonary decline 
in children with bronchiectasis.
7
 In PBB, recurrent exacerbations (>3/year, termed rPBB) and lower 
airway Hi infection are associated with future bronchiectasis.
3
 
 
Interventions targeting Hi more broadly may be efficacious in reducing exacerbations and improving 
clinical outcomes. Currently, the only licensed vaccine that may impact upon Hi is the 10-valent 
pneumococcal-H. influenzae protein D conjugate vaccine (PHiD-CV; Synflorix®, GlaxoSmithKline 
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Biologicals, Belgium). The protein D (PD) component is an outer membrane lipoprotein, which is 
antigenically conserved, surface located and present in most Hi (encapsulated and NTHi) strains.
8
 It is 
one of three Hi surface proteins (PD, P6 and OMP26) identified as potential vaccine antigens,
9
 with 
PD and P6 showing the most promise. Vaccine-induced anti-PD antibodies are associated with 
protective efficacy against Hi infection in middle ear and pulmonary clearance in rat disease models.
10
 
To date, no studies have evaluated PD-based vaccines in children with rPBB, CSLD or 
bronchiectasis.  
 
We aimed to determine the clinical efficacy, immune response, impact on nasopharyngeal carriage of 
Hi and safety of two doses of PHiD-CV in children with rPBB, CSLD or bronchiectasis. We tested 
the primary hypothesis that amongst children aged 18-months to <18-years with rPBB, CSLD or 
bronchiectasis, PHiD-CV reduces the incidence of respiratory exacerbations in the 12-months 
following two doses of vaccine compared to children who received a control  conjugate vaccine 
(quadrivalent meningococcal ACYW135, MenACYW135; Menactra, Sanofi Pasteur, Lyon).  
 
RESULTS 
Study cohort 
Between December 2012 and August 2015, 975 children were screened and 75 enrolled (63 onto the 
full clinical protocol and 12 onto the immunology only protocol) (Figure 1). One child was a screen 
failure (clinical protocol) and thus 74 children were randomised.  A participant on the clinical 
protocol was unblinded following dose-2 at the request of the ethics committee and following 
discussion with the Data Safety Monitoring Committee (DSMC) . This was after a severe local 
reaction to the 23-valent pneumococcal polysaccharide vaccine (PPV23), which was deemed 
unrelated to the study. However, this child was not included in the clinical analyses. Six children were 
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withdrawn from the study at parental request due to family commitments over the 14-months of the 
study and two were lost to follow-up (Figure 1). 
 
 
 
The mean age of the 74 children was 6.8 (standard deviation 3.7) years, 56.8% were male and at 
baseline the overall characteristics between the PHiD-CV and control vaccine groups  
(Table 1) were similar. Importantly, baseline prior pneumococcal vaccination history was comparable 
between the groups, in particular the proportion of those who had had at least three doses of a 
pneumococcal conjugate vaccine (PCV) and at least 1 dose of PPV23, as well as the median time in 
months since the last dose of either vaccine (Table 1). 
 
Clinical outcomes 
Amongst the 61 children included in the clinical analyses, the overall incidence density of acute 
exacerbations following dose 2 was 4.4 episodes per 100 child-weeks at risk (95% confidence interval 
(CI) 3.7, 5.2); the incidence density ratio (IDR) between the groups was  0.92 (95%CI 0.68, 1.32) 
(Table 2). Compared with MenACYW135, children receiving PHiD-CV had lower incidence rates for 
fortnights with respiratory symptoms (IDR 0.82, 95%CI 0.61, 1.10) and antibiotic short courses (ie. 
<14-days duration) (IDR 0.81, 95%CI 0.61, 1.09) (Table 2).  
 
To assess whether clinical findings may be confounded by use of azithromycin, we compared number 
and duration of azithromycin courses between the two groups. Overall, 55 courses were administered 
to 26/61 (42.6%) children during the study; 29 in 12/31 (38.7%) children in the PHiD-CV group and 
26 in 14/30 (46.7%) children in the MenACYW135 group. There was no difference in the median 
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duration of azithromycin courses between the two groups (PHiD-CV = 13.5-days; MenACYW135 = 
14-days). The proportion of long-term (>3-months) azithromycin use was also similar between groups 
(PHiD-CV=8/29, 27.6% and MenACYW135 group =5/26,19.2%). 
 
 
Data on hospitalised exacerbations were available for all 74 children; overall eight episodes were 
reported (1 in PHiD-CV group, 7 in MenACYW135 group). All episodes occurred post-dose 2. The 
IDR for hospitalised exacerbations in the PHiD-CV group compared to controls was 0.15 (95%CI 
0.01–0.95) across the entire period of follow-up and 0.16 (95%CI 0.01–1.02) for the period at risk 
post-dose 2. The single event in the PHiD-CV group occurred in a child with severe cerebral palsy; 
three of the seven events in the control group occurred in one child who also had severe cerebral 
palsy.   
 
Immunological outcomes 
The complete dataset for saliva and serum antibody titres at each study time-point by vaccine group 
are presented in Supplementary Tables 1-5.   
 
Salivary antibodies to H. influenzae and pneumococcal proteins (Supp Table 1) 
At baseline, there were no between-group differences in anti-PD saliva antibodies (p=0.238; Supp 
Table 1). However, between-group differences were observed for IgG antibodies to Hi proteins P6 
IgG and P26 IgG and for IgG antibodies to pneumococcal proteins PspA2 IgG  and Ply IgG with 
higher titres observed in the MenACYW135 vaccine group for all four proteins at baseline.  
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While no anti-PD saliva IgA response was observed at any time-point in the PHiD-CV group, anti-PD 
saliva IgG increased following both doses of vaccine and significant differences between the PHiD-
CV and MenACYW135 groups were sustained to 12-months following the second dose (Figure 2). In 
contrast, no saliva IgA or IgG responses were observed to Hi proteins P4, P6 and P26 or to any of the 
pneumococcal proteins. 
 
Salivary antibodies to pneumococcal polysaccharides (Supp Table 2) 
 
At baseline significant between-group differences were observed for saliva anti-pneumococcal 
polysaccharide IgG antibodies to serotypes 4, 5 and 7F with higher levels present in the 
MenACYW135 group. High-levels of 19A and 19F IgA and IgG antibodies were observed in both 
groups relative to the other serotypes. Increased saliva IgA and IgG concentrations occurred in all 
PHID-CV vaccine type anti-pneumococcal polysaccharide antibodies in the PHiD-CV group, but not 
in the MenACYW135 group. There were no saliva antibody responses to the two non-PHiD-CV 
pneumococcal serotypes, 3 and 19A. Although a persistent response was achieved for several 
serotypes, the difference between the groups was no longer significant at the 6-months post-dose 2 
time-point for serotypes 5, 6B, 9V, 19F and 23F for IgA, and 6B and 23F IgG antibodies respectively. 
Similarly, at  
12-months post-dose 2, there were no differences between groups for serotypes 1, 5, 6B, 7F, 9V, 19F 
and 23F for IgA, and 6B, 9V and 23F IgG antibodies respectively.   
 
Serum antibodies to H. influenzae and pneumococcal proteins (Supp Table 3) 
There were no baseline between-group differences in Hi and pneumococcal serum antibody geometric 
meant tires (GMT; Supp Table 3). Increases in serum anti-PD IgA were observed in the PHiD-CV 
group following the second dose and serum anti-PD IgG increased following the first dose (Figure 3). 
GMTs for anti-PD IgA and IgG antibodies were higher in the PHiD-CV than MenACYW135 group at 
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the 12-month post dose 2 time-point. There were no changes in serum IgA and IgG antibodies to P4, 
P6 and P26 nor to any of the pneumococcal proteins. 
 
 
 
Serum antibodies to pneumococcal polysaccharides (Supp Table 4) 
At baseline, the only between-group difference in anti-pneumococcal polysaccharide antibodies was 
for serotype 5 IgA, with higher levels in the MenACYW135 group. High levels of serum IgA 
antibodies to 19A and both IgA and IgG antibodies to 19F were observed relative to other serotypes. 
Specific IgA and IgG increases were observed following both doses in the PHiD-CV group for all 
PHiD-CV vaccine-type serotypes, which were not observed in the MenACYW135 group. These 
differences were sustained for the  
12-months following dose 2 for all serotypes other than 6B, 19F and 23F IgA, and 6B and 23F IgG 
antibodies respectively. No between-group differences at any time-point were observed for non-
vaccine serotypes 3 and 19A. 
 
Microbiological outcomes (Supp Table 5) At baseline, nasopharyngeal swab (NPS) cultures 
grew Hi in 2/36 (5.6%) children from the PHiD-CV group and 4/38 (10.5%) from the MenACYW135 
group. No between-group differences were observed in Hi prevalence at any time-point, although Hi 
was not isolated in the PHiD-CV group at the 6-month post-dose 2 time-point. The baseline 
prevalence of pneumococcus was 22.2% and 15.8% in the PHiD-CV and MenACYW135 groups 
respectively. Between-group differences of pneumococcus were observed only at the 2-months post-
dose 1 time-point (8.8% and 27% in the PHiD-CV and MenACYW135 groups respectively. 
Interpreting culture data was complicated by the high antibiotic use throughout the study, particularly 
azithromycin (Figure 4) and subsequently no further culture analyses were undertaken.   
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Of all swabs collected over the study period (n=320), Hi was identified in just 25, including four 
(16%) that were beta-lactamase positive. Overall, 18 (72%) Hi isolates were hpd positive and 19 
(76%) were fucP gene positive differentiating them from the commensal organism,  
H. haemolyticus. However, no differences in these characteristics existed between vaccine groups.  
 
Of the 51 culture positive swabs for pneumococci (n=18 in PHiD-CV group and n=33 in 
MenACYW135 group), serotypes 19F and 15B (7/51 (13.7%) for each serotype respectively) were the 
most common overall. While they were also the most common serotypes identified in the 
MenACYW135 group (5/33 (15.2%) for each serotype respectively), 22F and 23A were the most 
common in the PHiD-CV group (4/18 (22.2%) and 3/18 (16.7%) respectively) (Figure 5). Penicillin 
non-susceptible and macrolide-resistant isolates were each identified in 15/51 (29.4%) pneumococcal 
positive swabs and no differences in antibiotic resistance rates were observed between vaccine groups 
for either antibiotic.  
 
Safety outcomes 
Parent-completed diary cards were not available for three vaccine doses (one in the PHiD-CV group 
following dose 1 and one each in the MenACYW135 group after doses 1 and 2). The proportions of 
children reporting any local reaction in the 7-days post each vaccine dose were higher in the PHiD-
CV (94% and 91%) than the MenACYW135 group (56% and 50%) for each dose respectively (Figure 
6). There were no between-group differences in the 7-day general solicited and 30-day unsolicited 
symptoms. Of the local symptoms, pain was the most common (PHiD-CV 28/34 (82%) and 29/32 
(91%); MenACYW135 16/36 (44%) and (14/36 (39%) following the first and second doses 
respectively), most of which was mild and self-limiting. Pain was the only symptom to increase in 
severity following the second vaccine dose and only occurred in the PHiD-CV group (1 (3%) and 5 
 12 
(16%) after doses 1 and 2 respectively reported severe pain). None sought medical attention for these 
severe pain events. 
 
 
 
Nineteen serious adverse events (SAEs) were reported over the course of the study (5 PHiD-CV 
group; 14 MenACYW135 group). None were considered causally related to study vaccines. Of these 
SAEs, eight were for exacerbations of the child‟s pre-existing illness (see above). 
 
DISCUSSION 
 
Our study provides the first data on PHiD-CV in children with rPBB, CSLD and bronchiectasis. 
Despite not achieving the required sample size, and the consequent fragility of the data, we observed 
that compared with control children, those receiving PHiD-CV had fewer fortnights with respiratory 
symptoms and antibiotic courses although the difference was not statistically significant. Further, 
there were fewer hospitalised exacerbations in the PHiD-CV group, however the actual number of 
events and children were small. PHiD-CV also induced both serum and salivary anti-PD antibodies 
and was generally well-tolerated, despite higher proportions of recipients than controls experiencing 
local reactions following both vaccine doses. 
 
There are no comparable data with which to compare our findings. A Cochrane Review of six 
randomised controlled trials (RCTs) involving an oral, whole cell NTHi vaccine in 557 adults with 
either chronic obstructive pulmonary disease or chronic bronchitis found no effect on exacerbations or 
hospitalisations.
11
  However, a subgroup analysis of the  largest trial in the review, which was 
restricted to 91 subjects aged <65-years, reported efficacy (p<0.001) against all major endpoints, 
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including reductions of 54% in exacerbations, 22% in antibiotic courses and 62% in corticosteroid 
use.
12
 Notwithstanding the limitations associated with post-hoc analyses and the different patient 
populations, as a potential „proof of principle‟ the point estimate for reduced antibiotic use is similar 
to the 19% we observed in our study. Given worldwide concerns over increasing antibiotic 
resistance,
13
 our study provides promising preliminary data to suggest that PHiD-CV could decrease 
antibiotic use in children  with chronic pulmonary infections.  
 
We observed a reduction in fortnights with respiratory symptoms following both doses of the PHiD-
CV vaccine. The symptoms we recorded are common to both upper and lower respiratory infections 
and hence may include milder viral illnesses. We have not yet tested for viruses, but interactions 
between both Hi and pneumococci may be important. Hi colonisation of the airways alters immune 
responses to subsequent viral infections, potentially increasing susceptibility to exacerbations.
14
 
Further, there is growing evidence viruses predispose to pneumococcal infection by disrupting 
epithelial barriers and altering innate and adaptive immune responses, and that these actions can be 
ameliorated by pneumococcal vaccination.
15
 A caveat of finding a reduction in fortnights with 
respiratory symptoms is that the duration and consistency of symptoms were not measured and hence 
whether it was one or more events within and across fortnights was not accounted for in the analysis. 
 
The serum and salivary immune responses to vaccination in the study children suggest that except for 
saliva IgA, two doses of PHiD-CV induce significant boosting to anti-PD antibody and to most 
vaccine-type pneumococcal polysaccharide antibodies that persists for  
12-months following the second vaccine dose. IgA antibodies observed in saliva are indicative of 
stimulation of a mucosal immune response following vaccination, which may also be reflected at 
other mucosal sites, including the upper airways.
16
 Importantly, in this highly vaccinated population, 
there was no indication of hyporesponsiveness to the common polysaccharide antigens, although the 
limited sample size precluded analyses by prior vaccination status. Data in children and adults with 
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bronchiectasis suggest systemic deficiencies in IFN-ɣ production,17,18 especially in cytotoxic T-
lymphocytes and natural killer cells. In children, this systemic deficiency correlated with increased 
lower airway inflammation
17 
and importantly, the reduced IFN-ɣ production to Hi can be reversed 
following PHiD-CV vaccination.
19
 These data, together with the systemic and mucosal antibody 
responses observed in our study, and the preliminary clinical findings, suggest vaccination against Hi 
may be an important adjuvant to managing children with rPBB, CSLD and bronchiectasis. 
 
The NPS culture data in this study are difficult to interpret given the low proportion of positive 
specimens, and the frequent use of antibiotics during the study.
20
 At baseline, only 8.1% of NPS were 
culture positive for Hi and 18.9% were pneumococcus culture positive. This compares with positive 
NPS culture results of 30.6% and 29.5% for Hi and pneumococci respectively in Queensland children 
undergoing bronchoscopy for chronic cough during the same time period.
21
 The difference between 
the two studies, despite a similar distribution of children with PBB (not all recurrent), CSLD and 
bronchiectasis and the same laboratory performing the microbiology testing, is likely explained by 
children in the bronchoscopy study being newly-diagnosed with these chronic pulmonary infections, 
whereas children in our study were already receiving treatment for their disease. NPS collected while 
a child is anaesthetised for bronchoscopy may be of better specimen quality for culture. Azithromycin 
is used commonly in this patient population
22
 and in the current study over 40% of participants had 
received the antibiotic at least once during the trial. Azithromycin has long-term effects on 
carriage,
22,23
 lasting several months after ceasing therapy, and the small sample size and number of 
positive NPS cultures precluded differentiating trends in carriage between vaccine and antibiotic 
effects. 
 
PHiD-CV was generally well tolerated with most adverse events being mild, self-limiting and within 
the ranges reported in other studies.
24
 However, a higher proportion of children in the PHiD-CV group 
reported pain following both doses of vaccine compared to the MenACYW135 group and it was the 
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only reaction that increased in severity following the second vaccine dose. The most plausible 
explanation for this finding is that PHiD-CV contains an alum adjuvant, as do other PCVs (PCV7 and 
PCV13), and PPV23, while the MenACYW135 vaccine used in this study does not. Increasing 
reactogenicity with cumulative exposure to alum adjuvants in several vaccines, as experienced by 
children in the study, has been reported elsewhere and may reflect both local tissue damage and 
systemic inflammation induced by innate immune receptor activation.
25
  
 
The major limitation of our study is the premature termination of the study, resulting in the small 
sample size and inability to adequately address the primary endpoint and perform important subgroup 
analyses of the data, such as further exploration of potential baseline differences in exposure to 
household tobacco smoke. The reason for the imbalance is unknown, but is likely a reflection of the 
small numbers in each group (two children exposed in the 
 PHiD-CV group and seven in the MenACYW135 group). The challenges of recruitment included 
confirming eligibility criteria (particularly exacerbation history), the reluctance of parents to subject 
their child to further, non-essential medical intervention (including blood tests and further clinical 
studies) and competing studies in the same patient population. However, the trial‟s experience 
provides valuable information for the design and implementation of further studies. Secondly, we did 
not have a group that received a PCV only vaccine and hence there is uncertainty over whether the 
clinical outcomes we observed may be due to effects on pneumococcal infection, particularly given 
the boosting of pneumococcal antibodies. Further exploration of this possibility is also limited by the 
low proportion of pneumococcal culture positive swabs. Finally, approximately 40% of participants 
received azithromycin during the conduct of the study and given its prolonged effect upon the airways 
and the inability to model the data, we cannot definitively conclude that the effects we observed were 
not due to azithromycin.
26
  However, the number of children receiving azithromycin and the duration 
of the treatment courses was similar between the two study groups. 
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CONCLUSION 
Our study provides the first clinical and immunological data for a Hi vaccine, including one that also 
addresses pneumococcal infection, in children with rPBB, CSLD and bronchiectasis. It raises the 
possibility of important clinical effects warranting further investigation in this important group of 
children with chronic pulmonary disorders. However, the failure to achieve the required sample size 
and the lack of any statistically significant differences in our primary and secondary clinical outcomes 
means that our findings are instead hypothesis generating and require cautious interpretation. 
Consequently, these data will inform larger studies in a broader patient population, including adults, 
and serve to encourage future trials of candidate Hi vaccines.  
 
METHODS 
Design 
We conducted a multi-centre, parallel group, double-blind, RCT. The study protocol was published 
previously.
27
 Briefly, children aged 18-months to <18-years with rPPB, CSLD or bronchiectasis were 
recruited from specialist respiratory clinics in tertiary paediatric hospitals in Brisbane, Perth, Sydney 
and Melbourne and allocated randomly (1:1) to receive either PHiD-CV or quadrivalent 
meningococcal ACYW135 conjugate vaccine in a schedule of two doses, 2-months apart. Key 
exclusion criteria included cystic fibrosis, immunosuppressive conditions and prior receipt of either of 
the two study vaccines. Active surveillance was implemented via fortnightly parent/caregiver contact 
to capture acute exacerbations, respiratory symptoms, antibiotic/steroid use, SAEs and medically-
attended illnesses. Surveillance continued until 12-months following the second dose of vaccine. A 
respiratory exacerbation was defined as increased sputum volume or purulence, or ≥3-days of change 
in cough (>20% increase in cough score
28
 or type [dry to wet]).
29
  Exacerbations were classified by 
research staff following standardised parent/carer interviews. The trial was registered with the 
Australia and New Zealand Clinical Trials Registry (ACTRN12612000034831).  
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Published protocol changes 
The original protocol limited the upper age of participants to <15-years.
27
 Recruitment difficulties and 
limited funding meant the recruitment age was lifted to <18-years, another study site (Melbourne) was 
added in July 2014, and a change made to the primary objectives from the primary clinical endpoint 
of respiratory exacerbations to immunological endpoints (defined below). Children recruited from 
August 2014 entered the immunology cohort and no longer underwent active surveillance for non-
hospitalised exacerbations. Their clinical specimens were reduced to baseline and 1-month post-dose 
2 of study vaccine, with parents consenting to optional specimen taking at 12-months post-dose 2. 
Prior receipt of monovalent meningococcal C vaccine and a primary course of pneumococcal only 
conjugate vaccine were also removed from inclusion criteria. Hospitalisations for respiratory 
exacerbations were captured as part of SAE monitoring. Thus participants are those who followed 
either the full clinical protocol or the immunology protocol only. The independent DSMC approved 
secondary clinical endpoints (antibiotic use and frequency of any respiratory symptoms) being added 
to the pre-unblinding analysis plan for children on the clinical protocol. 
 
Ethics 
The Human Research Ethics Committees of all the participating institutions approved the study and 
all subsequent amendments. Parents/guardians and participants aged >12-years provided written 
informed consent.  A DSMC was established and independent study monitors conducted regular study 
audits. The trial was conducted under the Australian Therapeutic Goods Administration Clinical Trial 
Notification scheme. 
 
Objectives 
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The primary objective was to determine the efficacy of PHiD-CV in reducing respiratory 
exacerbations in children aged 18-months to <18-years with rPBB, CSLD or bronchiectasis. The 
secondary objectives were to:  
a) evaluate the efficacy of PHiD-CV in reducing antibiotic use and the incidence of 
fortnights where parents reported their child had respiratory symptoms; 
b) evaluate the serum and salivary antibody immune responses to PD, non-vaccine type Hi. 
proteins (P4, P6, P26) and PHiD-CV (1, 4, 5, 6B, 7F, 9V, 14, 18, 19F and 23F) and vaccine-
related pneumococcal serotypes (3 and 19A) at 2-months post-dose 1, and then at 1, 6 
and 12-months following the second vaccine dose; 
c) evaluate the impact of the PHiD-CV vaccine on nasopharyngeal carriage of  
Hi and pneumococcal vaccine-type and vaccine-related serotypes at  
2-months post-vaccine dose 1 and then at 1, 6 and 12-months following the second 
vaccine dose;   
d) evaluate local and systemic reactions to vaccine at 7 and 30-days after each dose and all 
SAEs for 14-months post-dose 1. 
 
Randomisation and masking 
An independent biostatistician prepared the randomisation code using a permuted blocking design 
(block size of 4) to maintain group balance.
27
 Randomisation was stratified by site (n=4), age (<6-
years and ≥6-years), and rPBB vs CSLD/bronchiectasis. Allocation concealment was achieved by 
consecutively numbered opaque sealed envelopes. Since the vaccines differed in colour and 
packaging, preparation and delivery was performed by nurses independent of the study and without 
blinded staff present. Blinding of investigators, study staff and participants was maintained until 
children on the clinical protocol had completed follow-up and the clinical data had been cleaned and 
locked and blinded analyses of the clinical data had been completed. With the approval of the DSMC 
and the coordinating ethics committee, unblinding was then performed with the exception of ongoing 
participants in the immunology only cohort. The laboratories performing all immunology and 
microbiology procedures remained blinded for the complete duration of the study. 
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Specimen collection and laboratory procedures 
In children enrolled in the full clinical protocol, serum, saliva and NPS were collected at enrolment 
and at 2-months post-vaccine dose 1, and then at 1, 6 and 12-months following the second vaccine 
dose. These specimens were also collected at enrollment and 1-month post-vaccine dose 2, with 
optional collection at 12-months post-dose 2 from children on the immunology protocol. Although 
parents and/or the child could refuse specimen collection, extra emphasis was placed on ensuring at 
least the baseline and 1-month post-dose 2 specimens were obtained. Specimens were processed using 
published procedures
27
 and stored locally at participating centres at -80
o
C before being transported 
frozen to the research laboratories.  
 
Outcomes 
The primary clinical outcome was the incidence of respiratory exacerbations in the  
12-months following the second vaccine dose. Child-time at risk of an exacerbation commenced 14-
days following receipt of the second vaccine dose and the denominator for calculating incidence 
densities also excluded the time when the child had an exacerbation. At least 14-days following the 
child‟s cough returning to baseline was required before a subsequent increase in symptoms was 
classified as a new exacerbation. The secondary clinical outcomes were the antibiotic courses 
prescribed for cough (courses <14-days or  
<28-days) and the frequency of fortnights when a parent/guardian reported respiratory symptoms 
during child-time at risk. Respiratory symptoms collected by nurses interviewing parents/carers at 
fortnightly surveillance contacts included any cough (ie wet or dry), parent-reported fever 
(+thermometer recording), nasal discharge/congestion, sore throat, wheeze, and difficulty breathing. 
Parents were educated on these symptoms at enrolment. As part of SAE surveillance, hospitalised 
exacerbations were recorded for all participants.  
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The primary immunological outcomes were serum and saliva IgA and IgG antibody titres to PD at 1-
month post-dose 2 for all participants. The secondary immunological outcomes were serum and saliva 
IgA and IgG antibody titres at 1-month post-dose 2 to Hi proteins P4, P6 and P26; pneumococcal 
proteins Ply, PspA1, PspA2 and CbpA; and pneumococcal polysaccharides 1, 3, 4, 5, 6B, 7F, 9V, 14, 
18, 19A, 19F and 23F. Where available, these Hi and pneumococcal antibody titres were also 
evaluated at 2-months post-dose 1, and at 6 and 12-months post-dose 2. The primary microbiological 
outcomes were culture-confirmed Hi and vaccine-type and vaccine-related pneumococci from NPS at 
each time-point.  
 
The co-primary safety outcomes were solicited local and general symptoms for 7-days following each 
vaccine dose, unsolicited reactions for 30-days following each vaccine dose and SAEs for 14-months 
following dose 1. 
 
Sample size 
Prospective data collected in Brisbane children with bronchiectasis attending a specialist respiratory 
clinic indicated a mean annual incidence of 2.1 (standard deviation 1.046) exacerbations requiring 
hospital clinic attendance or hospitalisation (Chang, unpublished data). Based on these data and 
results from the POET study (30% reduction in otitis media),
30
 our trial was powered to detect a 30% 
reduction from 2.1 to 1.47 exacerbations in the 12-months following the second vaccine dose. 
Assuming a Poisson distribution, 93 children per group would have provided 90% power (α=0.05, 2-
sided) to detect a 30% reduction in exacerbations in the PHiD-CV group and 80% power to detect a 
25% reduction. Assuming a 10% loss to follow-up, we aimed to recruit 206 children (103 per group). 
Differences <20% were considered unlikely to change clinical practice without additional supporting 
evidence. However, given recruitment difficulties and exhaustion of grant funds, the study was 
stopped after enrolling 75 children. 
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Analysis 
Demographic data were tabulated and expressed as proportions and/or means or medians of the 
selected characteristics by vaccine group with the corresponding 95%CI or interquartile ranges. The 
T-test for comparisons of means, Wilcoxon signed-rank test for medians and χ2 tests for comparison 
of proportions assessed between-group differences.  
 
Poisson regression was employed to calculate the primary endpoint and antibiotic use rate ratios and 
CIs, following assessment of distributional assumptions and using robust standard errors. The primary 
analysis compared the incidence density of respiratory exacerbations between the two groups with 
child-time at risk commencing 14-days following the second vaccine dose. As children are not at risk 
of an event while they are experiencing an event, the total duration of each event (in days) was 
subtracted from the total time of observation to obtain the child-time at risk denominator used in 
calculating incidence density rates. Absolute risk differences and IDRs were calculated to compare 
exacerbation incidence in the PHiD-CV and control groups respectively and presented with their 95% 
CIs. The same comparisons were performed for courses of antibiotics.  Fortnights with respiratory 
symptoms were counted on the basis of a “yes” or “no” parent response to whether or not the child 
had had any symptoms in that fortnight; individual symptoms and duration of symptoms within and 
between fortnights were not analysed for this paper. A log-binomial model, incorporating a robust 
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standard error and Bernoulli random variable was employed to calculate rate ratios for respiratory 
symptom fortnights. All analyses were performed on an intention-to-treat basis. 
 
Group-specific serum and saliva antibody responses to Hi and pneumococcal proteins and 
pneumococcal polysaccharide antigens were compared at each sampling time-point. Analyses were 
first performed using non-parametric methods (Wilcoxin signed-rank test). Data were then log-
transformed to assess normality and if normality assumptions were met, T-tests were used to compare 
transformed data, otherwise non-parametric methods were employed. Log-transformed data were then 
back-transformed and presented as GMTs with the corresponding 95%CIs. Proportions of children 
with Hi and pneumococcal nasopharyngeal carriage at each time-point were compared between 
vaccine groups and presented with their corresponding  
p-values. Safety data were analysed descriptively at each time-point with χ2 tests used to evaluate 
differences in the proportions of participants with solicited and unsolicited symptoms and SAEs at 
each study time-point. No adjustment was made for multiple testing. 
 
 
Role of the funding source 
The Australian National Health and Medical Research Council (NHMRC) funded this study 
(GNT1019904). The NHMRC had no role in the conception, design and implementation of the study, 
nor in the analysis and interpretation of data, the writing of the report and in the decision to submit the 
paper for publication. The vaccine manufacturers had no role in the study and vaccines were 
purchased at wholesale market prices from the distributors. 
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Figure legends  
 
Figure 1: Consort diagram.  
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Figure 2: Saliva anti-protein D IgA and IgG geometric mean antibody units per milligram of protein 
per millilitre (AU/mgP/mL), with corresponding 95% confidence intervals, by vaccine group and 
study time-point. 
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Figure 3. Serum anti-protein D antibody geometric mean titres (GMTs), with the corresponding 95% 
confidence intervals, by vaccine group and study time-point. 
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Figure 4: Haemophilus influenzae and pneumococcal culture-positive nasopharyngeal swabs, and 
antibiotic use in 14-days prior to each swab, by vaccine group and study time-point. Hi: H. influenzae, 
CSpn: capsular pneumococci, 14DayAB: any antibiotics in the 14-days prior to nasopharyngeal 
swab,14DayAZM: azithromycin in the 14-days prior to nasopharyngeal swab 
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Figure 5. Pneumococcal serotypes identified in nasopharyngeal swab cultures (n = 51 positive swabs) 
by vaccine group. *ON – Omni – negative: negative to pneumococcal omniserum (all pneumococcal 
serotypes) 
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Figure 6: 7-day local and general solicited reactions, and 30-day unsolicited symptoms, following 
each vaccine dose by study group. X: p<0.001. 
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Table 1. Baseline characteristics of children enrolled by vaccine group. 
 All children 
N = 74 
PHiD-CV 
N = 36 
MenACYW135 
N = 38 
Mean age in years (SD) 6.8 (3.7) 
 
6.9 (4.0) 6.6 (3.4) 
Male gender, n (%) 42 (56.8) 
 
22 (61.1) 20 (52.6) 
Respiratory diagnosis, n (%) 
Recurrent protracted bacterial bronchitis 
Chronic suppurative lung disease 
Bronchiectasis 
 
 
37 (50.0) 
22 (29.7) 
15 (20.3) 
 
17 (47.2) 
10 (27.8) 
9 (25.0) 
 
20 (52.6) 
12 (31.6) 
6 (15.8) 
Median age in years at diagnosis (IQR) 
 
2.3 (0 - 9) 2.3 (0 – 12) 2.2 (1 – 9) 
Median years since diagnosis (IQR) 3.1 (1.5 – 4.9) 2.9 (1.6 – 5.0) 3.5 (1.2 – 4.8) 
Prior immunisation history, n (%) 
Age appropriately immunized PCV 7 and/or 13¶ 
Prior PPV23 vaccination 
Influenza vaccine in past 12-months  
 
62 (83.7) 
22 (29.7) 
35 (47.3) 
 
32 (88.9) 
12 (33.3) 
18 (50.0) 
 
30 (78.9) 
10 (26.3) 
17 (44.7) 
Pneumococcal vaccination (PV) history, n (%) 
   7 and/or 13 valent PCV only 
      1 dose 
      2 doses 
      3 doses 
      4+ doses 
   PPV23 and: 
       1 dose of PCV 
       2 doses of PCV 
       3+ doses of PCV 
Summary: At least 3 doses of PCV 
 
 
5 (6.8) 
3 (4.1) 
31 (41.9) 
6 (8.1) 
 
1 (1.4) 
0 
17 (23.0) 
54 (73.0) 
 
 
4 (11.1) 
1 (2.8) 
13 (36.1) 
3 (8.3) 
 
1 (2.8) 
0 
9 (25.0) 
                  26 (72.2) 
 
 
1 (2.6) 
2 (5.3) 
18(47.3) 
3 (7.9) 
 
0 
0 
8 (21) 
29 (76.3) 
 36 
Median time in months since last dose PCV (IQR) 
Median months since PPV23 (IQR) 
Median time in months since any PV (IQR) 
60.8 (25.8 – 87.3) 
27 (17 – 44) 
39.5 (19.7 – 82.6) 
59.7 (25.8 – 97.5) 
27 (11 – 46) 
40.5 (19.5 – 77.2) 
63.1 (24.1 – 85.7) 
27 (20 – 45) 
39.0 (21.6 – 83.2) 
Median exacerbations past 18-months (IQR) 6 (4 – 10) 
 
6 (4 – 10) 5.5 (4 – 10) 
Hospitalised exacerbation in past 18-months, n (%) 
    Median hospitalisations past 18-months (IQR) 
27 (36.5) 
2.5 (1 – 4) 
 
15 (55.6) 
3 (1 – 5) 
12 (44.4) 
1.5 (1 – 3) 
Usually has cough when well, n (%) 
     Usual cough type 
           Wet 
            Dry 
           Variable 
     Mean usual day-time cough score* (SD) 
     Mean usual night-time cough score* (SD) 
40 (54.1) 
 
15 (37.5) 
15 (37.5) 
10 (25.0) 
1.7 (1.0) 
1.5 (1.1) 
19 (52.8) 
 
6 (31.6) 
7 (36.8) 
6 (31,6) 
1.8 (1.0) 
1.5 (1.0) 
21 (55.3) 
 
9 (42.8) 
8 (38.2) 
4 (19.0) 
1.6 (1.0) 
1.5 (1.3) 
Produces sputum during exacerbations, n (%) 
 
21 (28.3) 8 (22.2) 13 (34.2) 
Antibiotics within 14-days before enrolment, n (%) 
 
22 (29.7)  14 (38.9) 8 (21.6%) 
Long-term (>3-months) antibiotics at enrolment†, n (%) 
 
3 (4.1) 1 (2.8) 2 (5.3) 
Mean birthweight in grams (SD) 
 
2751 (1281) 2816 (1337) 2690 (1241) 
Median gestational age in weeks (IQR) 
 
38 (37 – 39) 38 (38 – 39) 38 (36 – 39) 
History of oropharyngeal aspiration, n (%) 
 
11 (14.9) 3 (8.3) 8 (21.1) 
Exposure to household tobacco smoke, n (%) 
 
9 (12.2) 2 (5.6) 7 (18.4) 
Maternal smoking during pregnancy, n (%) 
 
10 (13.5) 4 (11.1) 6 (15.8) 
Abbreviations. IQR, interquartile range; MenACYW135, quadrivalent meningococcal ACYW135 conjugate vaccine; No, number; PCV,  
pneumococcal conjugate vaccine; PHiD-CV 10-valent pneumococcal-H. influenzae protein D conjugate vaccine; PV, pneumococcal 
vaccination; SD, standard deviation; 23vPPV, 23-valent pneumococcal polysaccharide vaccine. 
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¶ Age appropriately immunised: received the recommended number of PCV vaccines in either infancy or as a catchup schedule from when 
the vaccine became available in Australia. *Validated parent-reported verbal descriptive cough score28 †All children were receiving long-
term Azithromycin 
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Table 2. Clinical endpoints by vaccine group. 
Endpoint PHiD-CV 
N =  31 
MenACYW135 
N = 30 
  
 n/time at risk 
(IR) 
n/time at risk 
(IR) 
IDR  
(95%CI) 
Risk Difference 
(95% CI) 
Exacerbations post-dose 2 71 / 1698-weeks 
(4.2 / 100-weeks) 
73 / 1549-weeks 
(4.7 / 100-weeks) 
0.92 (0.68, 1.32) -0.5/100-weeks 
(-2.0, 0.9) 
Exacerbations post-dose 1 106 / 1877-weeks 
(5.6 / 100-weeks) 
106 / 1637-weeks 
(6.5 / 100-weeks) 
0.97 (0.72, 1.45) -0.9/100-weeks 
(-2.5, 0.8) 
Fortnights with respiratory 
symptoms post-dose 2 
213 / 849 fortnights 
(25/100 fortnights) 
260 / 775 fortnights 
(34/100 fortnights) 
0.82 (0.61, 1.10) -8/100 fortnights 
(-14, -3) 
Fortnights with respiratory 
symptoms post-dose 1 
266 / 939 fortnights 
(28/100 fortnights) 
320 / 818 fortnights 
(39/100 fortnights) 
0.80 (0.59, 1.08) -11/100 fortnights 
(-16, -5) 
Antibiotic courses  
<14-days post-dose 2 
             80 / 1643 weeks 
(4.9/100 weeks) 
99/ 1668-weeks 
(5.9/100-weeks) 
0.81 (0.61, 1.09) -1.1 /100-weeks 
(-2.6, 0.1)  
 
Antibiotic courses   
<14-days post-dose 1 
106 / 1618-weeks 
(6.6/100-weeks) 
130 / 1637-weeks 
(7.9/100-weeks) 
0.82 (0.64, 1.06) -1.4/100-weeks 
(-3.2, 0.5) 
Antibiotic courses  
<28-days post-dose 2 
97 / 1597-weeks 
(6.1/100-weeks) 
107 / 1587-weeks 
(6.7 / 100-weeks) 
0.87 (0.66, 1.15) -0.7/100-weeks 
(-2.4, 1.1) 
Antibiotic courses  
<28-days post-dose 1  
128/1618-weeks 
(7.9/100-weeks) 
141/1606-weeks 
(8.8/100-weeks) 
0.95 (0.75, 1.21) -0.9/100-weeks 
(-2.9, 1.1) 
Abbreviations IDR, incidence density ratios; IR, incidence rate; N, number; PHiD-CV, 10-valent pneumococcal-H. influenzae protein D 
conjugate vaccine; MenACYW135,  quadrivalent meningococcal ACYW135 conjugate vaccine. 
 
 
